The following is a brief overview:

It is not permitted to submit work that has been published and/or is likely to be published before the Abstract Submission Deadline (3 April 2024, 18:00hrs. CEST). The Programme Committee has the right to remove an abstract if it contains data that has already been published. However, EASD accepts the submission of abstracts that have been presented in recent months at local or national diabetes meetings (e.g. ADA, DDG). An author submitting or presenting work that has been published in a journal before the EASD Abstract Submission Deadline will be banned from presenting data at the EASD Annual Meeting for three years.

Abstracts submitted on Human Studies:

The box must be marked stating that the study has been reviewed by the Local Ethics Committee and that it has therefore been performed in accordance with the ethical standards laid down in the Helsinki Declaration (see World Medical Association: www.wma.net).

Abstracts submitted on Animal Studies:

The box must be marked stating that the study has been carried out along the “Principles of laboratory animal care” (NIH Publication no. 85-23, revised 1985) and according to the national law, if applicable.

The abstract must be submitted as follows:

There is no limit to the number of abstracts an author may submit; however, an author may only serve as the presenting author on two submissions. It is the authors’ responsibility to designate a new presenter for presentation scheduling conflicts that arise. If accepted, the presenter must be a co-author listed on the abstract at the time of submission.

It is mandatory that the presenting author of any abstract accepted for presentation or discussion attends the EASD Annual Meeting 2024 in Madrid to present and/or discuss the paper.

Failure to do so, without prior or adequate explanation sent to the EASD Office by email, may result in the author or the institution being banned from presenting abstracts for the next three years.

Abstracts are welcome from non-members of EASD. Please refer to the Registration section of this General Information, regarding the date by which authors must become members of EASD in order to qualify for preferential registration fees. These regulations will be strictly enforced.

The abstract must be submitted in English. New authors should create an account using a login name and a password. With this information they can revise the submission as often as required to make changes, additions, amendments and change/add/delete authors. This is possible until the Abstract Submission Deadline on 3 April 2024, 18:00hrs CEST.After this date the submission site will be closed. IMPORTANT: Always double check that the “complete” status of your submitted abstract has not been affected after having edited it.

Your abstract submission must adhere the following structure:

• The maximum number of characters is 3,200 (excl. spaces) including the title and the author block. The title should be short (maximum 170 characters).
• Please enter your name and the names of co-authors as given in the example below. Start each name with a capital letter and continue in lower case, do not enter names/affiliations all in capital letters.
  First Name: John
  2nd Initial:  J
  3rd Initial:   R
  Last Name: Macleod
• The abstract must be structured. Enter each section into the corresponding text field with the provided sub-headings in bold (Background and aims:, Materials and methods:, Results: and Conclusion:). The abstract structuring words are fixed for each abstract text box. One or two sentences should describe the methods, and any aspects of methodology (e.g. use of control groups, randomisation, patient selection, assay variation). The sentences stating the results must include hard data, including statistical analysis. The abstract requires solid data, i.e. n, p-values and confidence intervals if appropriate.
• It is allowed to include only one table or one graph to your abstract, but 400 characters will be deducted from the maximum number of characters allowed. Tables must be uploaded as an image; so you must create your table and convert it into an image in order to include it in your abstract. You can edit your table or graph and then replace it, or delete it until the submission deadline on 3 April 2024, 18:00hrs CEST. Do not enter both (a table and a graph) in the same image file; also, do not create and upload multi panel images (a maximum of two panels is allowed). When creating a table, do not exceed a number of 10 columns and 12 rows with a maximum of 1 line per row.
• References are not allowed.
• For drugs exclusively generic names should be used (no trademarks).
• A list of approved abbreviations and units of expression for use without definition appears in Diabetologia.
• Grant/Support information must be entered into its designated field.
• Where applicable, the Clinical Trial Registration Number must be entered into its designated field; not in the abstract body.
• Only one keyword can be selected.
• Abstracts cannot be submitted as an e-mail attachment.

Once all submission steps have been successfully completed and the abstract deadline has passed, the presenting author will receive a notification confirming the final version of the abstract submission.

In case of questions, or if you have not received a notification confirming the final version of the abstract submission by 16 April 2024, please contact the EASD office: abstracts@easd.org

Keywords

One keyword from the list available here must be selected for the submission.

Scientific Programme Committee

Selection of abstracts for the Scientific Programme is made anonymously. Preference for oral presentation or short oral discussion is not possible.

The Scientific Programme Committee allocates the accepted abstracts to either an oral presentation or a short oral discussion session. The Scientific Programme Committee Members will meet in May 2024 and have the absolute right to accept or reject abstracts. Their decision is final.

Only accepted abstracts will be published in the Abstract Volume. The Scientific Programme Committee’s decision will be communicated via email in the last week of May 2024 only to the presenting (= first named) author’s contact email entered in the abstract submission system.

Short Oral Discussions

Short Oral Discussions rank equally with Oral Presentations at the EASD Annual Meeting.

A short PowerPoint presentation without audio must be uploaded to the EASD presentation management platform by the indicated deadline prior to the start of the Annual Meeting. Detailed instructions will be sent to the presenting (= first named) author’s contact email on notification of acceptance.

Short Oral Discussions during the EASD Annual Meeting will be delivered live and will be made available online as webcasts.

Oral Presentations

PowerPoint presentation will be available for Oral Presentations. Instructions on presentation will be sent to the presenting (= first named) author’s contact email on notification of acceptance. Only single projection is provided.

Oral Presentations during the EASD Annual Meeting will be delivered live and will be made available online as webcasts.

Publication of Abstracts

Accepted abstracts will be published in the Abstract Volume, a supplement issue of Diabetologia, the journal of the EASD. Furthermore abstracts accepted for presentation and discussion will be published on the EASD website from 1 July 2024.